{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-001155","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.165230+00:00","generated_at":"2026-06-07T04:04:52.964489+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Black Diamond provides 2024 milestones: Phase 2 data for BDTX-1535 in NSCLC expected Q3; cash into Q2 2025","bullets":["FDA feedback enables Phase 2 first-line cohort for BDTX-1535 in non-classical EGFR mutant NSCLC; Fast Track granted for second-line C797S.","Phase 2 results for second/third-line EGFR mutant NSCLC expected Q3 2024; Phase 1 and window-of-opportunity GBM data expected Q2 2024.","Phase 1 results for BDTX-4933 in KRAS mutant NSCLC expected Q4 2024.","Existing cash, cash equivalents and investments expected to fund operations into Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-001155","json":"https://secwatch.observer/filing/0001104659-24-001155.json","markdown":"https://secwatch.observer/filing/0001104659-24-001155.md","text":"https://secwatch.observer/filing/0001104659-24-001155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924001155/0001104659-24-001155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924001155/tm241770d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:04:52.964489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}